About This Deal
DONALDSON Co INC acquired Solaris Biotechnology S.r.l. for approximately EUR 41 million / $45.7 million (net of cash acquired), a transaction completed in November 2021, structured as all cash.
Solaris Biotechnology S.r.l. operates in Life Sciences, is based in Headquartered in Porto Mantovano, Italy; U.S. operations in Berkeley, California. Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and tangential flow filtration systems for use in pharma, food and beverage, biotechnology and other life sciences markets. Headquartered in Porto Mantovano, Italy, with U.S. operations based in Berkeley, California.
Expands Donaldson's bioprocessing equipment offering and establishes a Life Sciences manufacturing base in Europe.
Life Sciences segment (initially reported within IFS / Industrial Products)
Deal Terms
Transaction Details
In Their Words
On November 22, 2021, the Company acquired Solaris, headquartered in Porto Mantovano, Italy, with U.S. operations based in Berkeley, California, for cash consideration of approximately EUR 41 million, or $45.7 million, net of cash acquired. Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and tangential flow filtration systems.Donaldson FY2022 10-K, Note 2 Acquisitions
Advisors
Advisory firms were not disclosed for this transaction.
Related Deals & Entities
See how Top Bucket AI works for your firm
Request DemoStay ahead of private markets
Research and market intelligence for private-markets professionals.
You're subscribed.
Thanks for signing up.